VIDA streamlines respiratory clinical trials with artificial intelligence

VIDA Streamlines Respiratory Clinical Trials with Artificial Intelligence (AI)

Viewpoint Molecular Targeting™ Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors

NIH innovation grants propelling Viewpoint Molecular forward

ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement

Viewpoint Molecular Targeting® Partners with Industry Leader Pepscan to Accelerate Peptide Discovery Program

National report features UI startups that generate jobs and boost Iowa economy

EDC Client Case Study: Viewpoint Molecular Targeting

KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD